Improving Adjuvant Chemotherapy in Breast Cancer - Can We Get More for Less with TACT2?

Clinical Oncology

Volumn 19, Issue 8, 2007, Pages 593-595

  Johnson, L ^a   Cameron, D ^b   Barrett Lee, P ^c   Canney, P ^d   Bliss, J M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c VELINDRE CANCER CENTRE   (United Kingdom)

^d BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DNA; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAXANE DERIVATIVE;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RESEARCH; CLINICAL TRIAL; DNA DETERMINATION; DRUG EFFICACY; EARLY CANCER; EDITORIAL; GENE AMPLIFICATION; HEALTH CARE ORGANIZATION; HUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; EVIDENCE-BASED MEDICINE; FEMALE; FLUOROURACIL; HUMANS;

EID: 34548295821     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.06.016     Document Type: Editorial

References (18)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
2. Poole C.J., Earl H., Hiller L., et al., for the NEAT investigators and the SCTBG. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 355 (2006) 1851-1862
3. Barrett-Lee P., Ellis P., Bliss J., and on behalf of the TACT Trial Management Group. Duration of adjuvant chemotherapy; anthracyclines, taxanes and novel agents - more or less. Clin Oncol 14 (2002) 263-266
4. Burnell M, Levine M, Chapman JA, et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of an interim analysis. San Antonio Breast Cancer Symposium 2006 (abstract 53).
5. Ayers M., Symmans W.F., Stec J., et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22 (2004) 2284-2293
6. Stockler MR, Sourjina T, Harvey V, et al. A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. San Antonia Breast Cancer Symposium 2006 (abstract 6066).
7. Wunderlich A.K., and Schmalenberg H.S. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 14 (2003) 881-893
8. Woll P.J., Thatcher N., Lomax L., et al. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients. J Clin Oncol 19 (2001) 712-719
9. Huisman C., Biesma B., Postmus P.E., et al. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy. Br J Cancer 85 (2001) 1456-1461
10. Citron M.L., Berry D.A., Cirrincione C., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21 (2003) 1431-1439
11. Hudis C., Citron M., Berry D., et al. Five year follow-up of INT C9741: dose-dense chemotherapy is safe and effective. Breast Cancer Res Treat 94 (2005) S51
12. Fornier M.N., Seidman A.D., Lake D., et al. Increased dose-density (DD) is feasible: a pilot study of epirubicin and cyclophosphamide (EC) followed by paclitaxel (T), at 10-11 day interval with filgrastim support, for women with early breast carcinoma (BC). J Clin Oncol ASCO(23) (2005) (16S), 616
13. Venturini M., Del Mastro L., Aitini E., et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 97 23 (2005) 1724-1733
14. Leonard R.C., Miles D., Thomas R., et al., UK Breast Cancer Neutropenia Audit Group. Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 89 11 (2003) 2062-2068
15. Siena S., Piccart M.J., Holmes F.A., et al. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim in patients with stage II-IV breast cancer. Oncol Rep 10 3 (2003) 715-724
16. Lyman G.H., Dale D.C., and Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21 24 (2003) 4524-4531
17. The Adjuvant Breast Cancer Trials Collaborative Group. Polychemotherapy for early breast cancer: results from the International Adjuvant Breast Cancer Chemotherapy Randomized Trial. J Natl Cancer Inst 99 7 (2007) 506-515
18. The Adjuvant Breast Cancer Trials Collaborative Group. Ovarian ablation or suppression in premenopausal early breast cancer: results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial. J Natl Cancer Inst 99 7 (2007) 516-525